Federica De Paoli

Mrs. Federica De Paoli

enGenome srl, Pavia, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2022 in Genes
Verified
Journal Article
Open access
PDF file
ITIbrahim Taha
Ibrahim Taha
FPFederica De Paoli
Federica De Paoli
SFSelena Foroni
Selena Foroni
SZSusanna Ho Zucca
Susanna Ho Zucca
LLLimongelli Limongelli
Limongelli Limongelli
AMAntonella Minelli
Antonella Minelli
Introduction. Shwachman-Diamond Syndrome (SDS) is an autosomal-recessive disorder characterized by neutropenia, pancreatic exocrine insufficiency, skeletal dysplasia, and an increased risk for leukemic transformation. Biallelic mutations in the SBDS gene have been found in about 90% of patients. The clinical spectrum of SDS in patients is wide, and variability has been noticed between different patients, siblings, and even within the same patient over time. Herein, we present two SDS siblings (UPN42 and UPN43) carrying the same SBDS mutations and showing relevant differences in their phenotypic presentation. Study aim. We attempted to understand whether other germline variants, in addition to SBDS, could explain some of the clinical variability noticed between the siblings. Methods. Whole-exome sequencing (WES) was performed. Human Phenotype Ontology (HPO) terms were defined for each patient, and the WES data were analyzed using the eVai and DIVAs platforms. Results. In UPN43, we found and confirmed, using Sanger sequencing, a novel de novo variant (c.10663G > A, p.Gly3555Ser) in the KMT2A gene that is associated with autosomal-dominant Wiedemann–Steiner Syndrome. The variant is classified as pathogenic according to different in silico prediction tools. Interestingly, it was found to be related to some of the HPO terms that describe UPN43. Conclusions. We postulate that the KMT2A variant found in UPN43 has a concomitant and co-occurring clinical effect, in addition to SBDS mutation. This dual molecular effect, supported by in silico prediction, could help to understand some of the clinical variations found among the siblings. In the future, these new data are likely to be useful for personalized medicine and therapy for selected cases.

4 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
SSSarah L. Stenton
Sarah L. Stenton
MOMelanie O’leary
Melanie O’leary
GLGabrielle Lemire
Gabrielle Lemire
GVGrace E. VanNoy
Grace E. VanNoy
SDStephanie DiTroia
Stephanie DiTroia
AOAnne O’donnell-Luria
Anne O’donnell-Luria
Background: A major obstacle faced by rare disease families is obtaining a genetic diagnosis. The average “diagnostic odyssey” lasts over five years, and causal variants are identified in under 50%. The Rare Genomes Project (RGP) is a direct-to-participant research study on the utility of genome sequencing (GS) for diagnosis and gene discovery. Families are consented for sharing of sequence and phenotype data with researchers, allowing development of a Critical Assessment of Genome Interpretation (CAGI) community challenge, placing variant prioritization models head-to-head in a real-life clinical diagnostic setting. Methods: Predictors were provided a dataset of phenotype terms and variant calls from GS of 175 RGP individuals (65 families), including 35 solved training set families, with causal variants specified, and 30 test set families (14 solved, 16 unsolved). The challenge tasked teams with identifying the causal variants in as many test set families as possible. Ranked variant predictions were submitted with estimated probability of causal relationship (EPCR) values. Model performance was determined by two metrics, a weighted score based on rank position of true positive causal variants and maximum F-measure, based on precision and recall of causal variants across EPCR thresholds. Results: Sixteen teams submitted predictions from 52 models, some with manual review incorporated. Top performing teams recalled the causal variants in up to 13 of 14 solved families by prioritizing high quality variant calls that were rare, predicted deleterious, segregating correctly, and consistent with reported phenotype. In unsolved families, newly discovered diagnostic variants were returned to two families following confirmatory RNA sequencing, and two prioritized novel disease gene candidates were entered into Matchmaker Exchange. In one example, RNA sequencing demonstrated aberrant splicing due to a deep intronic indel in ASNS , identified in trans with a frameshift variant, in an unsolved proband with phenotype overlap with asparagine synthetase deficiency. Conclusions: By objective assessment of variant predictions, we provide insights into current state-of-the-art algorithms and platforms for genome sequencing analysis for rare disease diagnosis and explore areas for future optimization. Identification of diagnostic variants in unsolved families promotes synergy between researchers with clinical and computational expertise as a means of advancing the field of clinical genome interpretation.

29 March 2025 in NAR Genomics and Bioinformatics
Verified
Journal Article
Open access
FPFederica De Paoli
Federica De Paoli
GNGiovanna Nicora
Giovanna Nicora
SBSilvia Berardelli
Silvia Berardelli
AGAndrea Gazzo
Andrea Gazzo
RBRiccardo Bellazzi
Riccardo Bellazzi
SZSusanna Ho Zucca
Susanna Ho Zucca
The digenic inheritance hypothesis holds the potential to enhance diagnostic yield in rare diseases. Computational approaches capable of accurately interpreting and prioritizing digenic combinations of variants based on the proband’s phenotypes and family information can provide valuable assistance during the diagnostic process. We developed diVas, a hypothesis-driven machine learning approach that interprets genomic variants across different gene pairs. DiVas demonstrates strong performance in both classifying and prioritizing causative digenic combinations of rare variants within the top positions across 11 cases with the complete list of variants available (73% sensitivity and a median ranking of 3). Furthermore, it achieves a sensitivity of 0.81 when applied to 645 published causative digenic combinations. Additionally, diVas leverages explainable artificial intelligence to elucidate the digenic disease mechanism for predicted positive pairs.

3 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
FPFederica De Paoli
Federica De Paoli
GNGiovanna Nicora
Giovanna Nicora
SBSilvia Berardelli
Silvia Berardelli
AGAndrea Maria Gazzo
Andrea Maria Gazzo
RBRiccardo Bellazzi
Riccardo Bellazzi
SZSusanna Ho Zucca
Susanna Ho Zucca
Motivation: The digenic inheritance hypothesis holds the potential to enhance diagnostic yield in rare diseases. Computational approaches capable of accurately interpreting and prioritizing digenic combinations based on the proband’s phenotypic profiles and familial information can provide valuable assistance to clinicians during the diagnostic process. Results: We have developed diVas, a hypothesis-driven machine learning approach that can effectively interpret genomic variants across different gene pairs. DiVas demonstrates strong performance both in classifying and prioritizing causative pairs, consistently placing them within the top positions across 11 real cases (achieving 73% sensitivity and a median ranking of 3). Additionally, diVas exploits Explainable Artificial Intelligence (XAI) to dissect the digenic disease mechanism for predicted positive pairs. Availability and Implementation: Prediction results of the diVas method on a high-confidence, comprehensive, manually curated dataset of known digenic combinations are available at oliver.engenome.com .


9 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
Andrei Stefan BlinduAndrei Stefan Blindu
Andrei Stefan Blindu
SBSilvia Berardelli
Silvia Berardelli
FPFederica De Paoli
Federica De Paoli
FMFederico Manai
Federico Manai
RTRossella Tricarico
Rossella Tricarico
Paolo MagniPaolo Magni
Paolo Magni
Background/Objectives: DNA methylation is a key epigenetic process that regulates gene expression and is often disrupted in colorectal cancer (CRC). Aberrant methylation of promoter CpG islands can silence tumor suppressor genes and drive tumorigenesis. A subset of CRCs exhibits the CpG Island Methylator Phenotype (CIMP), characterized by widespread hypermethylation and distinct clinical outcomes. Identifying genes whose expression is epigenetically regulated by methylation is important for prioritizing candidate biomarkers and therapeutic targets in CRC. Methods: We developed and compared a series of computational approaches to identify genes whose expression is regulated by DNA methylation in The Cancer Genome Atlas (TCGA) cohort of Colon Adenocarcinoma (COAD) patients. Samples were stratified according to their CpG Island Methylator Phenotype (CIMP) level to capture distinct epigenetic subgroups. The proposed framework integrates methylation and transcriptomic data to systematically detect methylation–expression associations indicative of epigenetic regulation. Results: The best-performing method identified gene sets strongly associated with promoter methylation–expression relationships and enriched for pathways relevant to colorectal cancer progression and patient stratification. To evaluate the robustness and transferability of the approach, it was further validated on independent datasets, including Stomach Adenocarcinoma (STAD), Glioblastoma Multiforme (GBM), and Mesothelioma (MESO), supporting its robustness and potential generalizability across multiple tumor types. Conclusions: Our study highlights the potential of computational pipelines to uncover epigenetically regulated genes in colorectal cancer. The identified candidate genes provide a hypothesis-generating foundation for refining molecular stratification and guiding future studies aimed at epigenetic biomarker discovery and therapeutic hypothesis development.